Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.PRNewsWire • 04/09/26
Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 04/08/26
How to Play Lilly Stock Post Oral Obesity Pill Foundayo's ApprovalZacks Investment Research • 04/06/26
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug FightThe Motley Fool • 04/04/26
India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparationReuters • 04/03/26
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugsCNBC • 04/02/26
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?Zacks Investment Research • 04/02/26
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressureProactive Investors • 04/02/26